Commercially Available Prostaglandin Analogs for the F
Similarities and Differences

Survey of Ophthalmology

53, S69-S84

DOI: 10.1016/j.survophthal.2008.08.012

Citation Report

#	Article	IF	Citations
1	Update on the Mechanism of Action of Topical Prostaglandins for Intraocular Pressure Reduction. Survey of Ophthalmology, 2008, 53, S107-S120.	4.0	260
2	Role of prostaglandins and specific place in therapy of bimatoprost in the treatment of elevated intraocular pressure and ocular hypertension: A closer look at the agonist properties of bimatoprost and the prostamides. Clinical Ophthalmology, 2009, 3, 663.	1.8	12
3	Extracellular Release of ATP Mediated by Cyclic Mechanical Stress Leads to Mobilization of AA in Trabecular Meshwork Cells. , 2009, 50, 5805.		43
4	Beyond TGF-Î²: a prostaglandin promotes fibrosis. Nature Medicine, 2009, 15, 1360-1361.	30.7	33
5	Pharmacotherapy of intraocular pressure â€“ part II. Carbonic anhydrase inhibitors, prostaglandin analogues and prostamides. Expert Opinion on Pharmacotherapy, 2009, 10, 2859-2870.	1.8	47
6	Bimatoprost. Drugs and Aging, 2009, 26, 1049-1071.	2.7	20
7	Differences Between Applanation Tonometry and Dynamic Contour Tonometry in Prostaglandin Analogue-treated Eyes. Journal of Glaucoma, 2010, 19, 347.	1.6	2
9	IOP-lowering efficacy and tolerability of preservative-free tafluprost 0.0015% among patients with ocular hypertension or glaucoma. Current Medical Research and Opinion, 2010, 26, 1905-1913.	1.9	38
10	Interaction of topical alopecia and acne medications: notable stain enhancement by bimatoprost. Journal of the European Academy of Dermatology and Venereology, 2010, 24, 1487-1488.	2.4	1
11	Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension. Clinical Ophthalmology, 2010, 4, 741.	1.8	48
12	A Novel Nitric Oxide Releasing Prostaglandin Analog, NCX 125, Reduces Intraocular Pressure in Rabbit, Dog, and Primate Models of Glaucoma. Journal of Ocular Pharmacology and Therapeutics, 2010, 26, 125-132.	1.4	64
13	Emerging drugs for ocular hypertension. Expert Opinion on Emerging Drugs, 2011, 16, 137-161.	2.4	36
14	Thermal Stability of Bimatoprost, Latanoprost, and Travoprost Under Simulated Daily Use. Journal of Ocular Pharmacology and Therapeutics, 2011, 27, 51-59.	1.4	23
15	Neuroprotective effects of prostaglandin analogues on retinal ganglion cell death independent of intraocular pressure reduction. Experimental Eye Research, 2011, 93, 265-270.	2.6	46
16	First experience with BAK-free travoprost 0.004% in topical glaucoma medication. Clinical Ophthalmology, 2012, 6, 1.	1.8	9
17	Switching patients from preserved prostaglandin-analog monotherapy to preservative-free tafluprost. Clinical Ophthalmology, 2011, 5, 623.	1.8	33
19	Preservative-free tafluprost 0.0015% in the treatment of patients with glaucoma and ocular hypertension. Advances in Therapy, 2011, 28, 575-585.	2.9	26
20	Clinical Options for the Reduction of Elevated Intraocular Pressure. Ophthalmology and Eye Diseases, 2012, 4, OED.S4909.	1.2	40

#	Article	IF	Citations
21	The Cytotoxic Effects of Preserved and Preservative-Free Prostaglandin Analogs on Human Corneal and Conjunctival EpitheliumIn Vitroand the Distribution of Benzalkonium Chloride Homologs in Ocular Surface TissuesIn Vivo. Current Eye Research, 2012, 37, 145-154.	1.5	52
22	Ocular Drug Delivery for Glaucoma Management. Pharmaceutics, 2012, 4, 197-211.	4.5	54
23	Comparison of Human Ocular Distribution of Bimatoprost and Latanoprost. Journal of Ocular Pharmacology and Therapeutics, 2012, 28, 134-145.	1.4	23
24	Randomized crossover study of latanoprost and travoprost in eyes with open-angle glaucoma. Graefe's Archive for Clinical and Experimental Ophthalmology, 2012, 250, 123-129.	1.9	13
25	Bimatoprost protects retinal neuronal damage via Akt pathway. European Journal of Pharmacology, 2013, 702, 56-61.	3.5	13
26	Prodrugs: A challenge for the drug development. Pharmacological Reports, 2013, 65, 1-14.	3.3	177
27	A novel convergent synthesis of the potent antiglaucoma agent travoprost. Tetrahedron, 2013, 69, 1634-1648.	1.9	15
28	Therapeutic uses of prostaglandin F2Î± analogues in ocular disease and novel synthetic strategies. Prostaglandins and Other Lipid Mediators, 2013, 104-105, 109-121.	1.9	27
29	A Novel Convergent Synthesis of the Antiglaucoma PGF_{2Î±} Analogue Bimatoprost. Chirality, 2013, 25, 170-179.	2.6	11
30	Efficacy and safety of preservative-free latanoprost eyedrops, compared with BAK-preserved latanoprost in patients with ocular hypertension or glaucoma. British Journal of Ophthalmology, 2013, 97, 196-200.	3.9	82
31	Current status of unoprostone for the management of glaucoma and the future of its use in the treatment of retinal disease. Expert Opinion on Pharmacotherapy, 2013, 14, 105-113.	1.8	11
32	Preservative-free tafluprost in the treatment of naive patients with glaucoma and ocular hypertension. Clinical Ophthalmology, 2013, 7, 901.	1.8	12
33	Bimatoprost-Loaded Ocular Inserts as Sustained Release Drug Delivery Systems for Glaucoma Treatment: In Vitro and In Vivo Evaluation. PLoS ONE, 2014, 9, e95461.	2.5	64
34	The diurnal and nocturnal effects of travoprost in normal-tension glaucoma. Clinical Ophthalmology, 2014, 8, 2189.	1.8	5
35	Bimatoprost 0.01% vs bimatoprost 0.03%: a 12-month prospective trial of clinical and in vivo confocal microscopy in glaucoma patients. Eye, 2014, 28, 422-429.	2.1	24
36	The Prostaglandin F_{2Î±} Analog Fluprostenol Attenuates the Fibrotic Effects of Connective Tissue Growth Factor on Human Trabecular Meshwork Cells. Journal of Ocular Pharmacology and Therapeutics, 2014, 30, 237-245.	1.4	12
37	Incidence of deepening of the upper eyelid sulcus on treatment with a tafluprost ophthalmic solution. Japanese Journal of Ophthalmology, 2014, 58, 212-217.	1.9	38
38	Safety and efficacy of travoprost solution for the treatment of elevated intraocular pressure. Clinical Ophthalmology, 2015, 9, 633.	1.8	17

#	Article	IF	Citations
39	Acute corneal toxicity of latanoprost with different preservatives. Cutaneous and Ocular Toxicology, 2016, 35, 1-6.	1.3	9
40	Investigational and experimental drugs for intraocular pressure reduction in ocular hypertension and glaucoma. Expert Opinion on Investigational Drugs, 2016, 25, 1201-1208.	4.1	10
41	Recent Advances in Topical Ocular Drug Delivery. Journal of Ocular Pharmacology and Therapeutics, 2016, 32, 67-82.	1.4	136
42	Effect of preservativeâ€free tafluprost on intraocular pressure, pupil diameter, and anterior segment structures in normal canine eyes. Veterinary Ophthalmology, 2017, 20, 34-39.	1.0	15
43	Audible clicking on blinking: an adverse effect of topical prostaglandin analogue medication. Clinical and Experimental Ophthalmology, 2017, 45, 304-306.	2.6	6
44	Does the intraocular pressure-lowering effect of prostaglandin analogues continue over the long term?. International Ophthalmology, 2017, 37, 619-626.	1.4	5
45	Advances in the use of prodrugs for drug delivery to the eye. Expert Opinion on Drug Delivery, 2017, 14, 49-63.	5.0	39
46	Long term safety and tolerability of Tafluprost 0.0015% vs Timolol 0.1% preservative-free in ocular hypertensive and in primary open-angle glaucoma patients: a cross sectional study. BMC Ophthalmology, 2017, 17, 136.	1.4	20
47	The effect of cutaneous prostaglandin application on nail growth, nail brittleness, and intraocular pressure. Journal of Cosmetic Dermatology, 2018, 17, 263-267.	1.6	1
48	Preservative-Free Prostaglandin Analogs and Prostaglandin/Timolol Fixed Combinations in the Treatment of Glaucoma: Efficacy, Safety and Potential Advantages. Drugs, 2018, 78, 39-64.	10.9	43
49	Ocular hypotensive effects of prostaglandin analogs in Japanese patients with normal-tension glaucoma: a literature review. Clinical Ophthalmology, 2018, Volume 12, 1837-1844.	1.8	7
50	Randomized crossover trial comparing effectiveness and tolerability of generic and brand-name travoprost. Canadian Journal of Ophthalmology, 2019, 54, 223-228.	0.7	7
51	Effects of Preservative on the Meibomian Gland in Glaucoma Patients Treated with Prostaglandin Analogues. Chonnam Medical Journal, 2019, 55, 156.	0.9	13
52	Development and validation of the stability indicating RP-UHPLC method for the determination of the chemical purity and assay of bimatoprost. Journal of Pharmaceutical and Biomedical Analysis, 2019, 174, 348-359.	2.8	7
53	Medical Therapy for Glaucoma-IOP Lowering Agents. , 2019, , 115-135.		1
54	Effect of topical ophthalmic administration of 0.005% latanoprost solution on aqueous humor flow rate and intraocular pressure in ophthalmologically normal adult Beagles. American Journal of Veterinary Research, 2019, 80, 498-504.	0.6	3
56	Comparing glaucoma medications and general demographics in a sample of glaucoma patients treated in private practice with nationwide registry data in Finland. Acta Ophthalmologica, 2020, 98, 449-454.	1.1	5
57	Nanotechnology for Medical and Surgical Glaucoma Therapyâ€”A Review. Advances in Therapy, 2020, 37, 155-199.	2.9	39

#	Article	IF	Citations
58	The protective effect of 3% diquafosol on meibomian gland morphology in glaucoma patients treated with prostaglandin analogs: a 12-month follow-up study. BMC Ophthalmology, 2020, 20, 277.	1.4	5
59	Prodrugs and nanomicelles to overcome ocular barriers for drug penetration. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 885-906.	3.3	42
60	Acceptability, adherence and economic analyses of a new clinical pathway for the identification of non-responders to glaucoma eye drops: a prospective observational study. British Journal of Ophthalmology, 2020, 104, 1704-1709.	3.9	1
61	Corneal damage and its recovery after instillation of preservative-free versus preserved latanoprost eye drops. Cutaneous and Ocular Toxicology, 2020, 39, 158-164.	1.3	7
62	Primary Angle-Closure Disease Preferred Practice PatternÂ®. Ophthalmology, 2021, 128, P30-P70.	5.2	45
63	Prostanoid receptor agonists for glaucoma treatment. Japanese Journal of Ophthalmology, 2021, 65, 581-590.	1.9	27
64	Nanoemulsion as a feasible and biocompatible carrier for ocular delivery of travoprost: Improved pharmacokinetic/pharmacodynamic properties. International Journal of Pharmaceutics, 2020, 583, 119402.	5.2	64
65	Effects of Four Formulations of Prostaglandin Analogs on Eye Surface Cells. A Comparative Study. PLoS ONE, 2015, 10, e0129419.	2.5	5
66	Control Optimo para el Glaucoma Crónico Simple - Médico vs Quirúrgico. Highlights of Ophthalmology, 2012, 40, 9-17.	0.0	0
67	Preferred Control of Chronic Open Angle Glaucoma: Medications vs Surgery. Highlights of Ophthalmology, 2012, 40, 9-17.	0.0	0
68	Isolation, characterization, and docking studies of (Z)-isopropyl 7-((1R, 2R, 3R, 5S)-2-((1E,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 347 Td Tafluprost. Current Organic Synthesis, 2020, 17, .	1.3	0
69	Once-daily Preservative-free Topical Anti-glaucomatous Monotherapy â€“ A Better Approach?. European Ophthalmic Review, 2020, 14, 21.	0.3	0
70	Spanlastics nanovesicular ocular insert as a novel ocular delivery of travoprost: optimization using Boxâ€“Behnken design and inÂvivo evaluation. Journal of Liposome Research, 2022, , 1-11.	3.3	6
71	Ophthalmic prostaglandin analogs revisited - A systematic review of commonly used formulations. Kerala Journal of Ophthalmology, 2023, 35, 130-138.	0.1	0